www.perpetualcommotion.com
"Give with a free hand, but give only your own."
-- J.R.R. Tolkien The Children of Hurin
- YGS/YKS Yi-Gan San (YGS) -
General Information:
Names:
Wikipedia entry:
Dr. Ray Shahelien entry:
********************************************************************************************
Observations:
YGS/YKS
Yi-Gan San (YGS), Yokukansan (YKS)
See also Ferulic Acid
... I want to introduce you to a new
alternative medicine originally formulated by a Chinese
gentleman, Xue Kai and his son, Xue ji, in Ming dynasty China in
1555 as a remedy for restlessness and agitation in children. The
formulation is called Yi-Gan San (YGS), later adapted by the
Japanese and called Yokukansan (YKS) around the 5th
century. For brevity I will usually refer to the Japanese
version (YKS) as it has virtually all the accessible research.
The formulation of YGS and also YKS includes a mixture of dried
herbs: 4 g of Atractylodis lancea rhizome, 4g of Poria, 3 g of
Cnidii rhizome [Ferulic acid
is a component of Cnidii], 3 g of Angelicae radix, 2 g of
Bupleuri radix, 1.5 g of Glycyrrhizae radix and 3 g of Uncariae
uncis cum ramulus. The recommended dose is: 2,5 grams of YGS/YKS
powder (1.08 g extract) 3x/day. In Japan, YKS has been approved
by the Ministry of Health, Labour and Welfare as prescriptions
covered under the National health Insurance plan. It is widely
reported that the benefits of YGS/YKS are probably attributable
to the formulation as a whole, rather than to the individual
compounds...
http://alzheimers.infopop.cc/eve/forums/a/tpc/f/762104261/m/4384001397
Pilot study of pharmacological treatment for frontotemporal
dementia: effect of Yokukansan on behavioral symptoms.
Psychiatry
Clin Neurosci. 2010 Apr;64(2):207-10.
Kimura T,
Hayashida H, Furukawa H, Takamatsu J.
Source
Division of Clinical Research, National Hospital Organization
Kikuchi Hospital, 208 Fukuhara, Koshi, Kumamoto 861-1116, Japan.
tkimura@kikuti.hosp.go.jp
Abstract
The aim of the present study was to investigate the efficacy of
Yokukansan in improving behavioral symptoms of frontotemporal
dementia. This study was a prospective, open-label trial of daily
Yokukansan for 4 weeks in 20 frontotemporal dementia patients.
Yokukansan treatment was found to significantly improve scores for
the Neuropsychiatric Inventory and the Stereotypy Rating
Inventory. No adverse effects or significant changes in physical
findings and laboratory data occurred except for hypokalemia in
two cases. The results indicate that Yokukansan can alleviate the
behavioral symptoms of frontotemporal dementia. (The clinical
trial registration number is UMIN000002704).
PMID:20447015 [PubMed]
http://www.ncbi.nlm.nih.gov/pubmed/20447015
Five cases of frontotemporal dementia with behavioral symptoms
improved by Yokukansan
Kimura
T,
Hayashida
H,
Furukawa
H, Takamatsu J.
Psychogeriatrics
Volume
9,
Issue
1,
pages 38–43, March 2009 (Japanese Psychogeriatric Society)
Article
first published online: 27 MAR 2009
Abstract
Herein, we present five cases with frontotemporal dementia whose
behavioral symptoms were improved by Yokukansan, a traditional
Japanese medicine (Kampo). All five patients were prescribed
Yokukansan (7.5 g/day) to reduce their symptoms. The patients'
symptoms were evaluated comprehensively using the Neuropsychiatric
Inventory (NPI) and the Stereotypy Rating Inventory (SRI) before
and 4 weeks after Yokukansan treatment. The mean (± SD) scores on
the NPI and the SRI before treatment were 55.6 ± 5.4 and 22.2 ±
6.5, respectively. After treatment, these scores were 30.0 ± 7.8
and 11.6 ± 7.5, respectively. Yokukansan was effective for the
treatment of clinical symptoms in all five patients without
adverse effects and significant changes in laboratory data.
Although antipsychotic drugs have been used to control behavioral
symptoms, their associated adverse effects frequently impact on
the activities of daily living and quality of life of treated
patients. The present cases suggest significant improvement of
behavioral symptoms in frontotemporal dementia with Yokukansan
treatment, leading to probable benefit of the use of Yokukansan in
individuals with frontotemporal dementia.
DOI: 10.1111/j.1479-8301.2008.00261.x
Full
text:
http://onlinelibrary.wiley.com/doi/10.1111/j.1479-8301.2008.00261.x/full
********************************************************************************************
Known sources:
********************************************************************************************
Natural sources:
********************************************************************************************
References:
********************************************************************************************
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Home
Preface Brain Failure Notes Notes II
References pg. 1 References pg. 2
Nutritional Alternatives
Patricia's Protocol
Tauopathy
Discussion
Forum
Correspondence Newsletters Poems Memory Enhancement
Click to join tauopathies
********************************************************************************************
Questions or comments,
contact "perpetualcommotion.com" at gmail.com
Updated: July 2, 2012
Inception: July 2, 2012